Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental GlomerulosclerosisGlobeNewsWire • 11/30/20
Retrophin's (RTRX) CEO Eric Dube on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/08/20
Retrophin (RTRX) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/29/20
Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/14/20
Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 ReimaginedGlobeNewsWire • 10/09/20
Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA NephropathyGlobeNewsWire • 09/21/20
Retrophin, Inc. (RTRX) CEO Eric Dube on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/03/20
Retrophin (RTRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 07/23/20
Retrophin to Present at the BMO 2020 Prescriptions for Success Healthcare ConferenceGlobeNewsWire • 06/19/20
Retrophin's (RTRX) CEO Eric Dube on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20
Analysts Estimate Retrophin (RTRX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 04/28/20